User:kaitlynxjor861426

Table S1: EC50 data of rituximab, polatuzumab vedotin, the unconjugated clinical antibody, surrogate ADC, as well as unconjugated surrogate antibody from unique binding experiments with human Fcγ

https://kaitlynlpqc110741.blogdigy.com/helping-the-others-realize-the-advantages-of-pk-monkey-42143626